metformin has been researched along with Cancer, Second Primary in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer." | 7.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 6.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer." | 3.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 2.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Metformin use was associated with lower all-cause mortality (HR = 0." | 1.42 | Associations between diabetes medication use and risk of second breast cancer events and mortality. ( Boudreau, DM; Calip, GS; Hoskins, KF; Yu, O, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bens, A | 1 |
| Langballe, R | 1 |
| Bernstein, JL | 1 |
| Cronin-Fenton, D | 1 |
| Friis, S | 1 |
| Mellemkjaer, L | 1 |
| Kwon, M | 1 |
| Roh, JL | 1 |
| Song, J | 1 |
| Lee, SW | 1 |
| Kim, SB | 1 |
| Choi, SH | 1 |
| Nam, SY | 1 |
| Calip, GS | 1 |
| Yu, O | 1 |
| Hoskins, KF | 1 |
| Boudreau, DM | 1 |
| Higurashi, T | 1 |
| Hosono, K | 1 |
| Takahashi, H | 1 |
| Komiya, Y | 1 |
| Umezawa, S | 1 |
| Sakai, E | 1 |
| Uchiyama, T | 1 |
| Taniguchi, L | 1 |
| Hata, Y | 1 |
| Uchiyama, S | 1 |
| Hattori, A | 1 |
| Nagase, H | 1 |
| Kessoku, T | 1 |
| Arimoto, J | 1 |
| Matsuhashi, N | 1 |
| Inayama, Y | 1 |
| Yamanaka, S | 1 |
| Taguri, M | 1 |
| Nakajima, A | 1 |
| Lee, JH | 1 |
| Jeon, SM | 1 |
| Hong, SP | 1 |
| Cheon, JH | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
1 review available for metformin and Cancer, Second Primary
| Article | Year |
|---|---|
Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antineoplastic Agents; Antineoplas | 2019 |
1 trial available for metformin and Cancer, Second Primary
| Article | Year |
|---|---|
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Ne | 2016 |
3 other studies available for metformin and Cancer, Second Primary
| Article | Year |
|---|---|
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N | 2015 |
Associations between diabetes medication use and risk of second breast cancer events and mortality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Fem | 2015 |
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Colonoscopy; Colorectal Neoplasms; Diab | 2012 |